clinical trial · NCT06348264
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Peking University First Hospital·phase2·recruiting·n = 37
Salivary Gland Neoplasm DuctRezvilutamideLeuprolide Acetate
brief summary
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.
started
Oct 10, 2024
primary completion
Mar 30, 2029
completion
Mar 30, 2031
last updated
Sep 23, 2025
official title
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol